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G protein-coupled receptors (GPCRs) constitute a large family of receptor proteins
that sense molecular signals on the exterior of a cell and activate signal transduction
pathways within the cell. Modeling how an agonist activates such a receptor is
fundamental for an understanding of a wide variety of physiological processes and
it is of tremendous value for pharmacology and drug design. Inelastic electron
tunneling spectroscopy (IETS) has been proposed as a model for the mechanism by
which olfactory GPCRs are activated by a bound agonist. We apply this hyothesis to
GPCRs within the mammalian nervous system using quantum chemical modeling.
We found that non-endogenous agonists of the serotonin receptor share a particular
IET spectral aspect both amongst each other and with the serotonin molecule: a
peak whose intensity scales with the known agonist potencies. We propose an expe-
riential validation of this model by utilizing lysergic acid dimethylamide (DAM-57),
an ergot derivative, and its deuterated isotopologues; we also provide theoretical
predictions for comparison to experiment. If validated our theory may provide new
avenues for guided drug design and elevate methods of in silico potency/activity
prediction.
Significance Statement
This project provides a scheme by which the potency of small molecule drugs at their
target transmembrane receptor may be predicted by a recent theoretical model. This
is a vital task as the fundamental mechanism by which receptor proteins are activated
via quantum mechanical processes.
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INTRODUCTION
Quantum activity within biological systems and the applications of information theory
therein have drawn much recent attention1–5. Examples of systems that exploit such phe-
nomenon are: quantum coherence and entanglement in photosynthetic complexes6–15, quan-
tum mutations16,17, information theory and thermodynamics of cancers18,19,the avian mag-
netic compass20–23, tunneling behavior in the antioxidant breakdown of catechols present in
green tea24, enzymatic action25, olfaction26, and genetic coding27. G Protein-Coupled Re-
ceptors (GPCR) are the target for the greatest portion of modern therapeutic small molecule
medications28. Predictability of pharmacological efficacy and potency for new drugs prior
to a complex total synthesis can be aided by in silico methods such as pharmacophore mod-
eling, or the construction of homology models. Protein/agonist binding theory has been
described through variants of the Lock and Key model, originally proposed by Fischer29,
and the extensions thereof30. Although this theory has provided insights into free energy
changes associated with the formation of the activated protein/agonist complex, it has not
manifested sufficient capacity for the prediction ligand potency due to a lack of knowl-
edge concerning the mechanism by which the agonist activates the complex. Growth of
the computational power of modern machines as well as developments within the field of
computational chemistry and molecular modeling has afforded reconnaissance and scouting
methods in the field of drug design. Additionally methods such as QM/MM have been
used in studies of protein folding and generation of the protein-agonist activated complex.
Furthering our ability to predict information regarding the viability of molecules as drugs is
greatly important.
Early models attempting to account for predictability of agonist classification beyond
mere shape were those of odorant binding31,32; these works proposed a vibrational theory
of receptor activation. Vibrational theories were eventually disregarded for reasons that
include a lack of conceived mechanism and the inability of the protein (which undertakes
thermally driven random walks in their conformation) to detect the continuum of thermally-
activated, classical vibrations of the odorant. A recently suggested theory for olfactory
activation consists of a physical mechanism closely resembling Inelastic Electron Tunneling
Spectroscopy (IETS)26,33,34. The plausibility of time scales associated with this process
was verified to be consistent with relevant biological time-scales through Marcus theory35.
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Electron tunneling rates for the olfaction system have been calculated and support the
theory36. Furthermore, eigenvalue spectral analysis of odorant molecules has shown a high
correlation between the vibrations and odorant classification37.
We focus on an initial examination of the viability of the vibrational theory of protein
activation in cases involving protein-agonist binding within the central nervous system via
application of IETS theory as a predictor of potency as defined within38. Activation of
the 5-HT1A and 5-HT2A receptors is implicated as being associated with human hallucino-
genic responses39? ,40. We utilize a model of inelastic electron tunneling to describe the
protein/agonist complex in a manner that will utilize the vibrational frequencies of the
bound agonist to facilitate electron transfer within the activation site of the protein/agonist
complex. The prerequisite agonist information was collected through molecular quantum
mechanics calculations utilizing density function theory as well as normal mode analysis and
natural bonding order methods; necessary were the harmonic displacements, frequencies and
partial charges of each constituent atom. In Section II, we will first present a qualitative
discussion of the relationship between the tunneling model and the protein-agonist complex.
Section III will discuss the tunneling features of several 5-HT1A and 5-HT2A agonists, and
how these correlate with the potency of these molecules taken from previous studies41? . We
conclude with a proposed set of molecules that could be employed in experimental valida-
tion of the vibrational theory’s applicability in the central nervous system and present the
expected results in accordance with this proposed mechanism.
MAPPING THE MODEL INTO THE BIOLOGICAL SYSTEM
Application of the IETS model for the agonists protein environment requires mapping
several aspects of the IETS methodology into the biological system. The two-plate apparatus
of the tunneling junction herein represent the walls of the receptor site; more explicitly,
under electron transfer, the valance and conductance bands associated with each side of
the junction are mapped to specific HOMOs and LUMOs of particular residues comprising
the walls of the receptor. This dictates that energy transition detectable by the protein
should be the energy difference between electronic levels of residue side-chains or any bound
cofactors, such as a metal ion. This alteration of IETS also localizes the source of tunneling
electrons to a single residue side-chain; the implication is that electrons are not capable
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of distributed tunneling through the molecule in the manner of a doped analyte within a
junction. This lack of a spatial distribution of electron trajectories suggests that the act
of tunneling is localized to regions of the agonist molecule along the classical trajectory of
the tunneling electron between the site of the electron donor and the site of the electron
acceptor. This implies that not all local oscillators associated with a specific mode may
fully contribute to the current enhancement due to the fall-off of the charge-dipole coupling
between the tunneling electron and the local atomic oscillators.
Secondly, unlike the typical experimental IETS procedure, the analyte is not deposited
upon a surface, being encapsulated by the active site. There is no externally applied potential
within the receptor site which would have allowed for the scanning of energies; yet, it has been
suggested that an ionic cofactor, likely a calcium ion, could provide this driving field. The
implication of this is that the receptor is set to test the vibrational-assisted enhancement to
the electron tunneling rate at a specific energy, opposed to scanning a range of energies. The
electrostatic interactions which govern docking orientation would be a means of orienting the
endogenous agonists in such a way that the tunneling junction is appropriately aligned for
maximized electron transfer across the atoms responsible for the inelastic contribution. Non-
endogenous agonists would align with residues in a manner which may place energetically
appropriate vibrational modes of the agonist in proximity of the tunneling vector specific to
this protein, thus allowing for the activation of the receptor.
RESULTS
Generation of tunneling spectra was completed through the procedure described by
Turin26,42, and outlined within the Supplementary Material. This procedure is an adap-
tation of earlier inelastic tunneling literature43,44 and similarly uses arbitrary units (a.u.)
for the tunneling intensity. Our spectral procedure was validated by comparison of the spec-
tra of the formate ion, which is prevalent throughout experimental and theoretical literature
in IETS42. These a.u. are proportional to the conductance enhancement, as well as repre-
sentative of an enhancement to the magnitude of electrostatic charge-dipole interaction an
electron experiences during tunneling. Necessary information for implementing the calcula-
tions - outlined in the Supplementary Material - was collected through quantum chemical
calculations. Computations were performed using Density Functional Theory at the 6-311G
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basis-level, utilizing the B3LYP functional which serves well for organic hydrocarbons; in
contrast to similar previous works26,42. Expanded pseudopotential correlation consistent 5-
zeta basis was used for large atoms where necessary? . DFT was employed both due to its
high accuracy in transition dipole frequencies and due to a desire to avoid encroaching errors
associated with dissimilarities between analyte and parameter molecules in semi-empirical
methods. Initial applications of Hartree-Fock theory displayed the characteristic 0.8 factor
shift to the vibrational frequencies, which is less than desirable for ease of interpretation
of the vibrational spectra. Vibrational calculations utilize reduced modal displacements, µ;
proportional to the Cartesian displacement through the modal center-of-mass factor,
√
µ.
This factor arises due to use of center-of-mass coordinates within the classical theory after
application of the harmonic approximation during calculations of the normal modes. Nat-
ural bond order calculations were performed to yield the partial charges, qi attributed to
each atom constituting the agonist. Scaled Kronecker delta functions are plotted at the on-
resonance absorbance frequency of the mode; these functions were convolved with Gaussian
functions possessing a conservative FWHM of 25 cm−1, representing a very narrow thermal
distribution. The spectral width was introduced to allow for peak additions, while 25cm−1
was selected to avoid over estimations of peak breadth.
Assessment of vibrational bands from the 5-HT2A agonists which could facilitate the
inelastic transfer of electrons within the protein environment is of primary import. Ag-
onists of a particular protein would share a single spectral feature associated with the
inelastic transfer, as the same amino acid side-chains would be responsible for the elec-
tron donation and acceptance for a specific protein. Tunneling spectrum of several selected
5-HT2A agonists have been generated. LSD, was selected as it possesses a high potency
as well as activity at this particular serotonin receptor within the cortical interneurons45.
DOI (2,5-dimethoxy-4-Iodo-amphetamine) was selected due to its high selective for the 2A-
subtype receptor46. The remaining selected molecules are members of the 2C-X (4-X-2,5-
dimethoxyphenethylamine) class of psychedelic phenethylamines. All compounds selected
are known hallucinogens47–49 some first characterized by Alexander Shulgin in the compendia
works PiHKAL and TiHKAL50,51.
Figure 1 shows the tunneling spectra of select agonists (above the axis). The selection of
candidate peaks, possibly responsible for facilitating inelastic transfer, was performed using
the Spectral Similarity Index (SI), similar to that used for comparison of mass spectra52.
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FIG. 1. The tunneling spectrum of several known 5-HT2A agonists as well as the square of the tun-
neling PDF reflected below the energy axes; the square is used to highlight major spectral aspects.
The Spectral Similarity Index of each plot given in the inlay, noting that these similarity indices
allude to good spectral agreement with the reference spectrum, LSD. More detailed information is
provided within the Supplemental Material
The SI was taken over the entire spectral region and repeated for a scan of the local regions
with an overlapping step of 500cm−1 with a width of 1000cm−1. The SI is given by:
SI = 1−
√
|ai − bi|
N
(1)
Where, within the above equation, N is the normalization constant (the numerator per-
formed for spectra b and a = b); bi is the value of the spectra being analyzed at discrete
location i while a is a reference spectra. Being the most potent agonist, LSD was selected
as the reference spectra for our SI calculations. The SIs, both global and local scans, as-
sociated with each of the tunneling spectra can be found within a table provided in the
Supplementary Material. To highlight major aspects of the tunneling PDF, we squared the
function, exaggerating aspects which exhibit large tunneling amplitudes within the spectra
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(Figure 1 reflected below energy axis). The only broadly shared spectral aspects were those
at 1500cm−1. For a more thorough discussion of the spectral aspects, isotopic effects at func-
tional groups and density of states for these systems, please see the provided Supplementary
Materials.
The integral of the tunneling probability density was taken around the 1500 ± 35cm−1
region and compared to known EC50 data for compounds shown to be agonists of the 5-HT2A
receptor. The EC50 used within this paper is taken from Parrish et al41 who determined the
elevated levels of phosphoinositides associated with the activation of the 5-HT2A receptors of
the human A20 cell line employed within the experiement across a collection of compounds
from the phenethylamine (PEA, or 2C-X) and phenylisopropylamine (PIA, or DOX) classes.
The detection procedure was replicated from Kurrasch-Orbaugh et al.? . The selection of
data used for our comparison is provided within our Supplemental Material. Data was
selected from a single source, helping to assure uniformity in collection and determination,
while selecting and comparing members of specific families of molecules (i.e. PIA/PEAs)
helps to minimize drastic changes in their docking configurations which may affect potency.
The similarities granted by selecting compounds from families may not allow for substantive
prediction in the relative potency, beyond docking affinities; this can be seen by noting that
two PIAs, DOI and DOB, have similar docking affinities at the 5-HT2A receptor
? , while
possessing great differences in their potency? .
The effective concentrations of several phenethylamines were taken from41 and compared
to the local integrals of the tunneling PDF. This comparison exposes a possible correlation
to the inverse of the EC50 data, taken to be representative of the potency for each species
at the receptor. Results for the 1500cm−1 region are shown in Figures 2 and 3 for the DOX
class and 2C-X class molecules computed, respectively. Figures 2a and 3a give the tunneling
spectra for each molecule, Fig. 2b and 3b compare the integral values to the known EC50s.
As inelastic tunneling facilitated by a charge-dipole interaction is a highly local process
where the interaction potential falls-off as r−3 for non-parallel displacements. Modes not local
to the electron donor/acceptor sites will not maximally contribute to the electron transfer,
which is proposed to be responsible for protein activation. Particular modes in 2C-T-2 and
in Aleph-2 reside within the thioether (roughly 5 angstrom from the ring system); due to
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FIG. 2. (a) The tunneling spectra of several DOX class agonists as well as their molecular struc-
tures. (b) The inverse of the median effective concentration for the DOX class agonists plotted
against the tunneling probability within the region at 1500±35cm−1. The trend of tunneling in-
tensity follows roughly the trend of the agonist’s potency at the 5-HT2A receptor.
FIG. 3. (a) The tunneling spectra of several 2C-X class agonists as well as their molecular struc-
tures. (b) The inverse of the median effective concentration for the 2C-X class agonists plotted
against the tunneling probability within the region at 1500±35cm−1. The trend of tunneling in-
tensity follows roughly the trend of the agonist’s potency at the 5-HT2A receptor.
the non-locality of these oscillators, tunneling probability should be examined after having
removed their contributions from the spectra. Figures 2a and 3a present the tunneling
spectrum of 2C-T-2 and Aleph-2 disregarding these contributions. After correction for non-
local motions, the integrals are in good qualitative agreement with the inverse EC50.This
9
preliminary information supports a possible quantum mechanical origin for the activation of
sensory proteins. We shall propose a possible experimental validation of the theory within
the following section.
PROPOSED EXPERIMENT
Early findings suggest that both the lake whitefish and the American cockroach can
identify isotopologues of amino acids and pheromones, respectively53,54. Recent experiments
have shown that the common fruit fly presents both naive bias to and a potential for trained
aversion towards the isotopologues of acetophenone55, and reposte56. Recent works featur-
ing human subjects have shown that naive participants are incapable of discerning between
deuterated acetophenone57; a second study58presented evidence which suggests human ca-
pability at discerning deuterated variants of musk odorants. Other works have attempted to
identify the characteristic vibrations associated with particular odors59, yet have not explic-
itly considered an electron tunneling mechanism. In this spirit, we propose an experimental
procedure for testing this new iteration of the vibrational theory of protein activation in
vivo.
DAM-57 (N,N-dimethyllysergamide) is an ergot derivative with a mild hallucinogen effect
associated with activity at the 5-HT2A receptor. As it activates the same receptor, the above
discussed candidate peak should, and does, appear in the tunneling spectrum of DAM-57.
By using isotopologues of a single compound, we may minimize any differences which may
lead to alterations in either docking geometry or affinity for the activation site. It, however,
should be noted that binding isotope effects and kinetic isotope effects can cause differences
in the potency of compounds, but this effect rarely outstrips 10%? so any effect on the order
of 30
Using 1500 cm−1 as a central point, and recalling the applied FWHM, the modes con-
tributing to inelastic transfer are those at 1500 ±35 cm−1. Modes within that range have
motions associated with (in order of contribution): stretching of the amide methyl hydrogen;
stretching of the phenyl and indole hydrogens; and bending of the methyl hydrogen of the
tertiary amine.
Deuteration of the three phenyl hydrogens (DAM-57-i) yields a marginal attenuation in
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FIG. 4. The tunneling spectrum of several deuterium-isotopologues of DAM-57. Yellow highlights
have been given to the energy region which is assumed to be the active energy region for inelastic
tunneling transfer. Specific dueterations deplete the tunneling probability within this region, and
may effectively eliminate the agonism of the molecule within the 5-HT2A receptor.
intensity near 1500 cm−1, and small change in tunneling probability. DAM-57-ii displays a
reduction in the 3700 cm−1 region, N-H stretch, shifting weight to 2700 cm−1. Deuter-
ation of the indole amine results in almost no character change near the active region.
Pro-deuteration of a single amide methyl (DAM-57-iii) significantly decreases the tunneling
intensity in the 1500 cm−1 region. Continued deuteration of the amide system (DAM-57-vi),
reduces this peak to roughly one-half the pro-protium intensity. DAM-57-vi and DAM-57-v,
moiety co-deuteration scenarios, present very small alterations of the peak intensity when
compared to DAM-57-iii and DAM-57-vi, respectively.
Within the tunneling model, deuteration of the amide side chains should dampen the
activity of the molecule at the 5-HT2A receptor through a relative reduction in potency.
This conclusion is supported by the relative activity between DAM-57 and LSD. The flexible
ethyl amide of LSD has been found to be essential to its high activity39,40,60,61, and that the
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methyl analogue (DAM-57) is far less potent; the tunneling probability at the 1500 cm−1
region of DAM-57 is depleted when compared to that of LSD. Following this, a prediction
that further depletion of the tunneling probability within this region should continue to
diminish the potency at the receptor may be entertained. The intensity of the tunneling
spectrum of DAM-57-iv is roughly a third the pro-protium, and the probability density of
tunneling is roughly tenthed this implies a possible extreme loss of potency associated with
deuteration of the amide side-chains.
CONCLUSIONS
Herein we describe the agonist-protein system by an electron tunneling junction coupled
to a field of oscillating dipoles, representative of the constituent atoms of the agonist. The
oscillator field provides a secondary path for electron transfer between the donor and acceptor
states of the junction. This secondary inelastic path facilitates the transfer if and only if
the electron can donate a quantum of energy to the oscillator field. Using this method we
examined classes of agonists for the 5-HT2A receptor and found that all agonist, to varying
degrees, are capable of facilitating electron transfer within the same energy region. The
degree to which this tunneling is facilitated correlates roughly to the potency of the agonist
within our test cases. We examined the tunneling characteristics of isotopologues of these
agonists and predict that it may be possible to modulate or quench their agonist properties
though the isotope exchange of specific atoms. Also included is a proposed experimental
path to test the model described herein. We conclude that this mechanism is a candidate
for the activation step for some transmembrane proteins, and its examination may allow for
better prediction of candidate drug molecules and the possible ability to control agonism of
molecules.
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